Anne Sophie Bargnoux

Anne Sophie Bargnoux

Auto-generated profile, based on publicly available information

Anne Sophie Bargnoux

Department of Biochemistry, University of Montpellier 1, Montpellier, France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Clinica Chimica Acta
Verified
Journal Article
Closed access
NKNils Kuster
Nils Kuster
JCJean Paul Cristol
Jean Paul Cristol
ECEtienne Cavalier
Etienne Cavalier
ABAnne-Sophie Bargnoux
Anne-Sophie Bargnoux
JHJean-Michel Halimi
Jean-Michel Halimi
PDPierre Delanaye
Pierre Delanaye

23 November 2010 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
ABAnne-Sophie Bargnoux
Anne-Sophie Bargnoux
ECEtienne Cavalier
Etienne Cavalier
JCJean Paul Cristol
Jean Paul Cristol
NSNoémie Simon
Noémie Simon
ADanne marie dupuy
anne marie dupuy
GMGeorges Mourad
Georges Mourad
Background: The potential use of cystatin C was recently assessed in kidney transplantation. A new particle-enhanced turbidimetric immunoassay (PETIA) that uses sheep antibodies (Binding Site human cystatin C immunoassay) has been developed. Analytical performance of this new assay was evaluated. Clinical relevance was determined by comparison with a reference method in a cohort of kidney transplant patients. Methods: First, the analytical performance of the Binding Site cystatin C kit was tested on SPAPLUS ® and Hitachi® analyzers. Second, a comparison study was performed using SPAPLUS ® analyzer against two other cystatin C methods (the Siemens-PENIA method on BNII® and the Dako-PETIA application on Olympus AU640®). Third, the glomerular filtration rate (GFR) was estimated using several predictive cystatin C- and creatinine-based equations and compared to GFR measured by an isotopic method (99mTc-DTPA). These predictive algorithms were analyzed with respect to bias, precision and accuracy. Results: Total intra-assay and inter-assay coefficients of variation were below 5%. Values obtained with the SPAPLUS ® correlated with the Siemens-PENIA and the Dako-PETIA methods. The creatinine and cystatin C-based equation allowed reliable assessment of GFR in our population of renal transplantation. Conclusions: The use of algorithms based on cystatin C and creatinine could provide a reliable estimate of GFR in kidney transplantation.

1 December 2016 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
ABAnne-Sophie Bargnoux
Anne-Sophie Bargnoux
TSThibault Sutra
Thibault Sutra
SBStéphanie Badiou
Stéphanie Badiou
NKNils Kuster
Nils Kuster
ADanne marie dupuy
anne marie dupuy
JCJean Paul Cristol
Jean Paul Cristol
Many patients are maintained at the lower end of the tacrolimus (TAC) reference range (3-7 ng/mL), requiring the use of analytical methods displaying a very low limit of quantification for their follow-up. Therefore, the new Dimension TAC, based on affinity chrome-mediated immunoassay technology, was evaluated on the Dimension EXL Integrated Chemistry System (Siemens Healthcare Diagnostics Inc). The aims of this study were (1) to evaluate the analytical performances with special emphasis on sensibility at low levels of TAC, (2) to compare the results with an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) method. Analytical performance (imprecision, linearity, limit of detection, and limit of quantification) was evaluated. Comparison to UPLC/MS/MS was performed on 106 whole blood samples from 88 transplant recipients using regression analysis and Bland-Altman plot analysis. Repeatability and within-laboratory coefficients of variation were <6% at mean TAC control levels of 3.7, 11.7, and 19.2 ng/mL. Linearity was confirmed between 1.0 and 22 ng/mL. Passing-Bablok regression analysis of Siemens TAC assay in comparison with UPLC/MS/MS values displayed a slope of 1.09 and an intercept of -0.42. Using Bland-Altman analysis, the mean bias was 0.27 ng/mL with 1.96 SD limits of -2.14 and 2.67 ng/mL. The new Dimension TAC immunoassay on the EXL analyzer demonstrated reliable and reproducible performances allowing routine monitoring in transplant patients, even at TAC concentrations at the lower end of the therapeutic range.

26 July 2017 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
ADanne marie dupuy
anne marie dupuy
QCQuentin Chevrier
Quentin Chevrier
YOYan Olejnik
Yan Olejnik
ABAnne Sophie Bargnoux
Anne Sophie Bargnoux
SBStéphanie Badiou
Stéphanie Badiou
JCJean Paul Cristol
Jean Paul Cristol

1 January 2016
Verified
Closed access
GBGuilaine Boursier
Guilaine Boursier
AAAntoine Avignon
Antoine Avignon
NKNils Kuster
Nils Kuster
CBCatherine Boegner
Catherine Boegner
ELElodie Leprieur
Elodie Leprieur
ariane sultanariane sultan
ariane sultan

1 January 2012
Verified
Journal Article
Closed access
ABAmandine Barrot
Amandine Barrot
ADanne marie dupuy
anne marie dupuy
SBStéphanie Badiou
Stéphanie Badiou
ABAnne Sophie Bargnoux
Anne Sophie Bargnoux
JCJean Paul Cristol
Jean Paul Cristol